Wave Life Sciences (WVE) Income from Continuing Operations (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Income from Continuing Operations came in at 69355000.0 in Q2 2026, down 37.42% YoY from 110827897.76 in Q2 2025, and down 165.86% on a QoQ basis from 26087000.0 in Q1 2026.
Powered by 
Analysis
Wave Life Sciences (WVE) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Income from Continuing Operations data on file, last reported at 69355000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 37.42% year-over-year to 69355000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 202473000.0 (down 55.9% YoY) and the FY2025 annual result came in at 204378000.0, down 110.68% from the prior year.
- Income from Continuing Operations eased to 69355000.0 in Q2 2026, from 26087000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 29253000.0 in Q4 2024 to a low of 69355000.0 in Q2 2026.
- A 5-year average of 34231333.33 and a median of 38409000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 279.7% in 2024, down 949.21% in 2024.
- Tracing WVE's Income from Continuing Operations over 5 years: stood at 43709000.0 in 2022, then soared by 62.76% to 16279000.0 in 2023, then surged by 279.7% to 29253000.0 in 2024, then slumped by 281.79% to 53179000.0 in 2025, then plunged by 30.42% to 69355000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 69355000.0 (Q2 2026), 26087000.0 (Q1 2026), and 53179000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Wave Life Sciences | 987.40 Mn | 619.39 Mn | - | -69.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69.36 Mn |
| Mar 31, 2026 | -26.09 Mn |
| Dec 31, 2025 | -53.18 Mn |
| Sep 30, 2025 | -53.85 Mn |
| Jun 30, 2025 | -50.47 Mn |
| Mar 31, 2025 | -46.88 Mn |
| Dec 31, 2024 | 29.25 Mn |
| Sep 30, 2024 | -61.78 Mn |
| Jun 30, 2024 | -32.92 Mn |
| Mar 31, 2024 | -31.56 Mn |
| Dec 31, 2023 | -16.28 Mn |
| Sep 30, 2023 | 7.28 Mn |
| Jun 30, 2023 | -21.10 Mn |
| Mar 31, 2023 | -27.41 Mn |
| Dec 31, 2022 | -43.71 Mn |
| Sep 30, 2022 | -39.00 Mn |
| Jun 30, 2022 | -41.30 Mn |
| Mar 31, 2022 | -37.81 Mn |
| Dec 31, 2021 | -34.79 Mn |
| Sep 30, 2021 | -6.23 Mn |